Effect of extractions from Ephedra sinica Stapf on hyperlipidemia in mice

Fan,Yanbo; Li,Jingjing; Yin,Qiang; Zhang,Yisheng; Xu,Huifang; Shi,Xinhua; Li,Chen; Zhou,Yan; Zhou,Caixin

doi:10.3892/etm.2014.2117

Effect of extractions from Ephedra sinica Stapf on hyperlipidemia in mice

Authors:
- Yanbo Fan
- Jingjing Li
- Qiang Yin
- Yisheng Zhang
- Huifang Xu
- Xinhua Shi
- Chen Li
- Yan Zhou
- Caixin Zhou
View Affiliations

Affiliations: State Administration of Traditional Chinese Medicine of P.R.C (Level Three), Laboratory of Traditional Chinese Medicine Preparation, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430014, P.R. China, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, P.R. China, Humanwell Healthcare Group Co., Ltd., Wuhan, Hubei 430000, P.R. China
Published online on: December 8, 2014 https://doi.org/10.3892/etm.2014.2117
Pages: 619-625

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the hypolipidemic and antioxidant potential of ephedra extractions in diet‑induced hyperlipidemic mice. Mice were fed a diet high in fat to establish the hyperlipidemic model. A total of 48 mice were randomly divided into six groups, which included the normal control, model control, positive control, ephedra alkaloid, ephedra polysaccharide and ephedra non‑alkaloid groups. Intragastric administration of the respective treatments was provided continuously for four weeks and the body weight was recorded weekly. The total levels of cholesterol (TC), triglycerides (TG), high‑density lipoprotein cholesterol (HDL‑C) and malondialdehyde (MDA), and the activity levels of superoxide dismutase (SOD), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum were recorded. In addition, changes in liver morphology and organ coefficients (ratio of organ to body weight) were evaluated, while the acute toxicity reactions of ephedra extractions were investigated using the modified Spearman‑Karber method. Compared with the mice in the model control group, the weight, liver coefficient, serum levels of TC, TG and MDA, and activities of ALT and AST were significantly lower (P<0.05) in the mice in the ephedra non‑alkaloid group. However, the level of HDL‑C and the activity of SOD were markedly higher (P<0.05). Fatty degeneration of the liver in the ephedra alkaloid and non‑alkaloid groups was notably improved compared with the model control group. The mean lethal dose (LD50) of ephedra alkaloids was 610 mg/kg, and the maximum tolerated dose of oral ephedra non‑alkaloids in the mice was 367.5‑fold larger than the clinical dosage in humans. In conclusion, ephedra non‑alkaloids have therapeutic potential for the treatment of hyperlipidemia, since they are able to improve lipid metabolism and are relatively safe for use under the maximum tolerated dose.

View Figures

View References

1	Lind L and Lithell H: Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J. 125:1494–1497. 1993. View Article : Google Scholar : PubMed/NCBI
2	Colomé C, Martínez-González J, Vidal F, de Castellarnau C and Badimon L: Small oxidative changes in atherogenic LDL concentrations irreversibly regulate adhesiveness of human endothelial cells: effect of the lazaroid U74500A. Atherosclerosis. 149:295–302. 2000. View Article : Google Scholar : PubMed/NCBI
3	Steinberg D: Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 95:1062–1071. 1997. View Article : Google Scholar : PubMed/NCBI
4	Cockerill GW, Saklatvala J, Ridley SH, et al: High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol. 19:910–917. 1999. View Article : Google Scholar : PubMed/NCBI
5	Khan BV, Harrison DG, Olbrych MT, Alexander RW and Medford RM: Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA. 93:9114–9119. 1996. View Article : Google Scholar : PubMed/NCBI
6	Assmann G and Schulte H: The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 116:1713–1724. 1988. View Article : Google Scholar : PubMed/NCBI
7	Chiu JH, Abdelhadi RH, Chung MK, et al: Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol. 95:490–491. 2005. View Article : Google Scholar : PubMed/NCBI
8	Maron DJ, Fazio S and Linton MF: Current perspectives on statins. Circulation. 101:207–213. 2000. View Article : Google Scholar : PubMed/NCBI
9	Kohli P, Desai NR, Giugliano RP, et al: Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 35:385–391. 2012. View Article : Google Scholar : PubMed/NCBI
10	Armitage J: The safety of statins in clinical practice. Lancet. 370:1781–1790. 2007. View Article : Google Scholar : PubMed/NCBI
11	Neuvonen PJ, Niemi M and Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 80:565–581. 2006. View Article : Google Scholar : PubMed/NCBI
12	Conforti A, Magro L, Moretti U, et al: Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Drug Saf. 29:1163–1172. 2006. View Article : Google Scholar : PubMed/NCBI
13	Abourashed EA, El-Alfy AT, Khan IA and Walker L: Ephedra in perspective - a current review. Phytother Res. 17:703–712. 2003. View Article : Google Scholar : PubMed/NCBI
14	Soni MG, Carabin IG, Griffiths JC and Burdock GA: Safety of ephedra: lessons learned. Toxicol Lett. 150:97–110. 2004. View Article : Google Scholar : PubMed/NCBI
15	Kuang H, Yonggang X, Yang B, Wang Q and Wang Y: Screening and comparison of the immunosuppressive activities of polysaccharides from the stems of Ephedra sinica Stapf. Carbohydrate Polymers. 83:787–795. 2011. View Article : Google Scholar
16	Xia Y, Kuang H, Yang B, Wang Q, et al: Optimum extraction of acidic polysaccharides from the stems of Ephedra sinica Stapf by Box-Behnken statistical design and its anti-complement activity. Carbohydrate Polymers. 84:282–291. 2011. View Article : Google Scholar
17	Shekelle PG, Hardy ML, Morton SC, et al: Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 289:1537–1545. 2003.PubMed/NCBI
18	Kalman D, Incledon T, Gaunaurd I, Schwartz H and Krieger D: An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults. Int J Obes Relat Metab Disord. 26:1363–1366. 2002. View Article : Google Scholar : PubMed/NCBI
19	Haller CA and Benowitz NL: Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 343:1833–1838. 2000. View Article : Google Scholar : PubMed/NCBI
20	al-Khalil S, Alkofahi A, el-Eisawi D and al-Shibib A: Transtorine, a new quinoline alkaloid from Ephedra transitoria. J Nat Prod. 61:262–263. 1998. View Article : Google Scholar : PubMed/NCBI
21	Purev O, Pospísil F and Motl O: FPaOM: Flavonoids from Ephedra sinica Stapf. Collect Czech Chem Commun. 53:3193–3196. 1988. View Article : Google Scholar
22	Starratt AN and Caveney S: Quinoline-2-carboxylic acids from Ephedra species. Phytochemistry. 42:1477–1478. 1996. View Article : Google Scholar
23	Konno C, Mizuno T and Hikino H: Isolation and hypoglycemic activity of ephedrans A, B, C, D and E, glycans of Ephedra distachya herbs. Planta Med. 162–163. 1985. View Article : Google Scholar : PubMed/NCBI
24	Chumbalov TK, Chekmeneva LN and Polyakov VV: Phenolic acids of Ephedra equisetina. Chemistry of Natural Compounds. 13:238–239. 1977. View Article : Google Scholar
25	Zhang L, Zou G and Yang T: Studies on extraction of water-soluble polysaccharides and the function of cleaning oxygen free-radical function of ephedra. Amino Acids and Biotic Resources. 22:24–26. 2000.
26	OECD (Organisation for Economic Co-operation and Development). OECD Guidelines for the Testing of Chemicals. Guideline 425: Acute Oral Toxicity-Up-and-Down Procedure. 1932001.
27	Karber G: Determination of LD50. Arch Exp Pathol Pharma. 162:4801931.
28	Wilson PW, Abbott RD and Castelli WP: High density lipoprotein cholesterol and mortality. The Framingham Heart Study Arteriosclerosis. 8:737–741. 1988.
29	Assmann G and Nofer JR: Atheroprotective effects of high-density lipoproteins. Annu Rev Med. 54:321–341. 2003. View Article : Google Scholar
30	Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM and Pridham JB: The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res. 22:375–383. 1995. View Article : Google Scholar : PubMed/NCBI
31	Tripathi YB, Singh BK, Pandey RS and Kumar M: BHUx: a patent polyherbal formulation to prevent atherosclerosis. Evid Based Complement Alternat Med. 2:217–221. 2005. View Article : Google Scholar : PubMed/NCBI
32	Ljubuncic P, Dakwar S, Portnaya I, et al: Aqueous extracts of Teucrium polium possess remarkable antioxidant activity in vitro. Evid Based Complement Alternat Med. 3:329–338. 2006. View Article : Google Scholar : PubMed/NCBI
33	Punitha IS, Rajendran K and Shirwaikar A and Shirwaikar A: Alcoholic stem extract of Coscinium fenestratum regulates carbohydrate metabolism and improves antioxidant status in streptozotocin-nicotinamide induced diabetic rats. Evid Based Complement Alternat Med. 2:375–381. 2005. View Article : Google Scholar : PubMed/NCBI
34	Toyokuni S, Tanaka T, Kawaguchi W, et al: Effects of the phenolic contents of Mauritian endemic plant extracts on promoter activities of antioxidant enzymes. Free Radic Res. 37:1215–1224. 2003. View Article : Google Scholar
35	Ralay Ranaivo H, Rakotoarison O, Tesse A, et al: Cedrelopsis grevei induced hypotension and improved endothelial vasodilatation through an increase of Cu/Zn SOD protein expression. Am J Physiol Heart Circ Physiol. 286:H775–H781. 2004. View Article : Google Scholar
36	Paradis V, Mathurin P, Kollinger M, et al: In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol. 50:401–406. 1997. View Article : Google Scholar : PubMed/NCBI
37	Yadav D, Hertan HI, Schweitzer P, Norkus EP and Pitchumoni CS: Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol. 97:2634–2639. 2002. View Article : Google Scholar : PubMed/NCBI
38	Kako KJ: Free radical effects on membrane protein in myocardial ischemia/reperfusion injury. J Mol Cell Cardiol. 19:209–211. 1987. View Article : Google Scholar : PubMed/NCBI
39	Harris ED: Regulation of antioxidant enzymes. FASEB J. 6:2675–2683. 1992.PubMed/NCBI
40	Limdi JK and Hyde GM: Evaluation of abnormal liver function tests. Postgrad Med J. 79:307–312. 2003. View Article : Google Scholar : PubMed/NCBI
41	State Pharmacopoeia Commission of the People’s Republic of China. Pharmacopoeia of the People’s Republic of China. 8th edition. People’s Medical Publishing House; Beijing: Part 1. pp. 2242005